Curated News
By: NewsRamp Editorial Staff
November 09, 2026
Lifordi's LFD-200 Shows Promise in Phase 1 for Autoimmune Disorders
TLDR
- Lifordi's LFD-200 Phase 1 data shows a subcutaneous ADC with anti-inflammatory effects and no cortisol suppression, positioning it ahead in autoimmune treatment.
- LFD-200 is an antibody-drug conjugate that delivers glucocorticoids directly to immune cells, with Phase 1 data showing dose-responsive anti-inflammatory activity and no serum cortisol impact.
- Lifordi's LFD-200 could improve autoimmune disease treatment by reducing systemic toxicity, potentially making tomorrow better for patients with rheumatoid arthritis.
- Lifordi Immunotherapeutics presented Phase 1 data for LFD-200, a subcutaneous ADC for autoimmune disorders, with rheumatoid arthritis patient data expected by end of 2026.
Impact - Why it Matters
This news matters because LFD-200 could revolutionize the treatment of autoimmune and inflammatory disorders by delivering potent anti-inflammatory effects without the systemic toxicity associated with traditional glucocorticoids. If successful, this approach could provide a safer, more tolerable option for patients with conditions like rheumatoid arthritis, potentially improving quality of life and reducing long-term side effects. The ongoing Phase 1b study in RA patients will be a critical next step in validating this innovative therapy.
Summary
Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company based in Burlington, MA, has announced positive Phase 1 clinical data for its lead candidate LFD-200, a novel subcutaneously administered antibody-drug conjugate (ADC) that delivers a potent glucocorticoid directly to immune cells. The data, presented at the American College of Rheumatology (ACR) Convergence 2026 conference, showed that LFD-200 was well tolerated in healthy participants across single and multiple ascending doses, with dose-responsive anti-inflammatory effects and no impact on serum cortisol—a sensitive marker for systemic glucocorticoid toxicity. This suggests that LFD-200 may offer the anti-inflammatory benefits of glucocorticoids without the typical systemic side effects.
The company is now evaluating LFD-200 in an ongoing Phase 1b study in patients with moderate to severe rheumatoid arthritis (RA), with initial data anticipated by the end of 2026. Lifordi’s innovative approach leverages the success of ADCs to develop treatments for autoimmune and inflammatory disorders. In addition to LFD-200, the company is applying its drug delivery platform to other payloads such as antisense oligonucleotides (ASOs), siRNA, and small molecules. Backed by leading investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, visit www.lifordi.com and follow the company on LinkedIn. To view the full announcement, including downloadable images, bios, and more, click here.
Source Statement
This curated news summary relied on content distributed by Reportable. Read the original source here, Lifordi's LFD-200 Shows Promise in Phase 1 for Autoimmune Disorders
